Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV DNA-C CN54ENV and CN54gp140 Vaccine Delivery Study (CUTHIVAC002)
NCT02589795Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Aug 2016
- Primary completion
- Dec 2017
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DNA-C + CN54ENV and CN54gp140 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Imperial College London. Primary endpoints: Primary Safety Endpoint at Week 22 and Primary Immunogenicity at Week 22. Started Aug 2016; status: completed.
02
Drugs
DNA-C + CN54ENVCN54gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02589795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589795.